Company profile: Fate Therapeutics
1.1 - Company Overview
Company description
- Provider of iPSC-derived cellular therapeutics and platform technologies, offering a proprietary clonal master iPSC platform for off-the-shelf therapies; CAR T and CAR NK candidates including FT819 (CD19 for systemic lupus erythematosus and other autoimmune diseases), FT522 (CAR NK with alloimmune defense receptor for B-cell lymphoma and autoimmune diseases), FT825 (HER2 solid tumors), plus NK and T-cell programs for cancer.
Products and services
- FT522: An iPSC-derived CAR NK cell product candidate incorporating alloimmune defense receptor technology to treat B-cell lymphoma and autoimmune diseases
- FT819: An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19, engineered to treat systemic lupus erythematosus and other autoimmune diseases
- IPSC Platform: A proprietary platform that engineers genetically modified, clonal master iPSC lines employed to develop standardized, off-the-shelf cellular therapy products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Fate Therapeutics
EOS
HQ: Italy
Website
- Description: Provider of biopharmaceutical research and development focused on creating novel medicines for the treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EOS company profile →
Salmedix
HQ: United States
Website
- Description: Provider of oncology drug development focused on hematologic malignancies (blood cancers). Primary product SDX-105 is marketed by healthcare professionals in Germany for several types of blood cancers; conducts Phase II clinical trials for SDX-105 in the U.S. and Canada.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salmedix company profile →
Cleveland Diagnostics
HQ: United States
Website
- Description: Provider of efficacious, affordable cancer diagnostic tests, including IsoPSA, a blood test designed to improve the accuracy of prostate cancer detection and reduce unnecessary biopsies by distinguishing cancer-related PSA proteins, and the Solvent Interaction Analysis Platform, which measures structural differences in proteins to identify cancer biomarkers and facilitate development of blood tests for cancer diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cleveland Diagnostics company profile →
Clarient
HQ: United States
Website
- Description: Provider of cancer diagnostic testing and oncology diagnostic services in the United States, partnering with local pathologists and oncologists to bring the standard of care back to their communities, using multiple technologies to clarify complex problems, help diagnose cancer cases, and provide insight.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarient company profile →
Revolution Medicines
HQ: United States
Website
- Description: Provider of RAS(ON) inhibitors for RAS-addicted cancers, including RMC-6236 (multi-selective), RMC-6291 (G12C-selective), and RMC-9805 (G12D-selective); and a tri-complex inhibitor platform enabling creation of inhibitors that target the active state of RAS proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revolution Medicines company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Fate Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fate Therapeutics
2.2 - Growth funds investing in similar companies to Fate Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Fate Therapeutics
4.2 - Public trading comparable groups for Fate Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →